Which are the causes of Chediak Higashi Syndrome?

Chediak-Higashi syndrome is a rare, life-threatening genetic disorder caused by mutations in the LYST gene, which regulates the transport of proteins within cellular structures called lysosomes. These mutations disrupt the formation of giant, dysfunctional granules in cells, leading to impaired immune function, partial albinism, and progressive neurological issues.

What is the genetic cause of Chediak-Higashi syndrome?

The primary cause of Chediak-Higashi syndrome is an autosomal recessive mutation in the LYST gene (Lysosomal Trafficking Regulator), located on chromosome 1q42. Because the condition is autosomal recessive, a child must inherit two copies of the mutated gene—one from each parent—to manifest the disease. This gene is responsible for the "shipping" of materials to lysosomes, which are the cell's recycling centers. When the LYST gene is faulty, these vesicles become abnormally large and cannot fuse correctly with other cell components, effectively "clogging" the cell's internal transport system.

How does this genetic defect impact the body?

In Chediak-Higashi syndrome, the cellular "clogging" primarily affects cells that rely on vesicle secretion, such as immune cells and pigment-producing cells. The physiological consequences include:

• Impaired Immune Response: Natural killer cells and cytotoxic T-cells cannot release their toxic granules to destroy viruses or bacteria, leading to severe, recurrent infections.


• Partial Albinism: Melanin granules cannot be properly distributed, resulting in lighter skin, hair, and eye pigmentation.


• Neurological Dysfunction: The accumulation of giant granules in neurons can eventually lead to ataxia, tremors, and cognitive decline.

Is there a difference between causes and risk factors?

For Chediak-Higashi syndrome, there are no environmental "risk factors" like diet or lifestyle that trigger the disease. The cause is strictly genetic. While the LYST mutation is the cause, the severity and "acceleration" of the disease (often called the "accelerated phase") can be triggered by viral infections, such as the Epstein-Barr virus, which causes an overactive, uncontrolled immune response known as hemophagocytic lymphohistiocytosis.

What is the current research into the etiology?

Current research focuses on gene therapy and hematopoietic stem cell transplantation (HSCT) as the only curative treatment for Chediak-Higashi syndrome. Scientists are investigating how to correct the LYST protein pathway to prevent the formation of giant granules, which could eventually offer a non-transplant-based approach for patients managing this rare condition.

Next steps

• Consult with a clinical geneticist to confirm the diagnosis via LYST gene sequencing.


• Connect with the 3 members living with Chediak-Higashi syndrome on DiseaseMaps.org to share experiences and coping strategies.


• Consult an immunologist regarding prophylactic antibiotics and potential evaluation for stem cell transplantation.

Medical disclaimer: This content is for informational purposes only and does not constitute professional medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Chediak-Higashi syndrome overview.


• Orphanet: Rare disease database entry for Chediak-Higashi syndrome (ORPHA:166).


• OMIM (Online Mendelian Inheritance in Man): Entry #214500 (LYST gene).


• PubMed/NCBI: Clinical reviews on the pathophysiology of lysosomal trafficking regulators.